347 related articles for article (PubMed ID: 28626179)
1. Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab.
Tanaka A; Inaguma D; Watanabe Y; Ito E; Kamegai N; Shimogushi H; Shinjo H; Koike K; Otsuka Y; Takeda A
Intern Med; 2017; 56(12):1531-1535. PubMed ID: 28626179
[TBL] [Abstract][Full Text] [Related]
2. Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report.
Zenti MG; Stefanutti C; Sanga V; Altomari A; Fabris A; Dauriz M; Bonora E
J Clin Apher; 2018 Aug; 33(4):546-550. PubMed ID: 29638018
[TBL] [Abstract][Full Text] [Related]
3. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Evolocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01).
Torres E; Goicoechea M; Hernández A; Rodríguez Ferrero ML; García A; Macías N; Anaya F
J Clin Apher; 2020 Jan; 35(1):9-17. PubMed ID: 31663632
[TBL] [Abstract][Full Text] [Related]
5. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
Lappegård KT; Enebakk T; Thunhaug H; Hovland A
Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
[TBL] [Abstract][Full Text] [Related]
8. Marked aortic valve stenosis progression after receiving long-term aggressive cholesterol-lowering therapy using low-density lipoprotein apheresis in a patient with familial hypercholesterolemia.
Tsuchida M; Kawashiri MA; Tada H; Takata M; Nohara A; Ino H; Inazu A; Kobayashi J; Koizumi J; Mabuchi H; Yamagishi M
Circ J; 2009 May; 73(5):963-6. PubMed ID: 19088396
[TBL] [Abstract][Full Text] [Related]
9. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
[TBL] [Abstract][Full Text] [Related]
10. LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response.
Lappegård KT; Enebakk T; Thunhaug H; Ludviksen JK; Mollnes TE; Hovland A
J Clin Lipidol; 2016; 10(6):1481-1487. PubMed ID: 27919366
[TBL] [Abstract][Full Text] [Related]
11. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.
Baum SJ; Sampietro T; Datta D; Moriarty PM; Knusel B; Schneider J; Somaratne R; Kurtz C; Hohenstein B
J Clin Lipidol; 2019; 13(6):901-909.e3. PubMed ID: 31759938
[TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia.
Zwiener RJ; Uauy R; Petruska ML; Huet BA
J Pediatr; 1995 May; 126(5 Pt 1):728-35. PubMed ID: 7751996
[TBL] [Abstract][Full Text] [Related]
13. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
[TBL] [Abstract][Full Text] [Related]
14. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
Marais AD; Naoumova RP; Firth JC; Penny C; Neuwirth CK; Thompson GR
J Lipid Res; 1997 Oct; 38(10):2071-8. PubMed ID: 9374129
[TBL] [Abstract][Full Text] [Related]
15. Treatment of severe hypercholesterolemia by LDL-apheresis: cholesterol-lowering effect and clinical evaluation.
Saito Y; Shinomiya M; Shirai K; Yoshida S
Beitr Infusionsther; 1988; 23():160-71. PubMed ID: 2484772
[No Abstract] [Full Text] [Related]
16. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
17. The first results demonstrating efficiency and safety of a double-column whole blood method of LDL-apheresis.
Hequet O; Le QH; Rigal D; Mekhloufi F; Jaeger S; Sassolas A; Groisne L; Moulin P
Transfus Apher Sci; 2010 Feb; 42(1):3-10. PubMed ID: 19932056
[TBL] [Abstract][Full Text] [Related]
18. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT
J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346
[TBL] [Abstract][Full Text] [Related]
19. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.
Lappegård KT; Kjellmo CA; Ljunggren S; Cederbrant K; Marcusson-Ståhl M; Mathisen M; Karlsson H; Hovland A
Transfus Apher Sci; 2018 Feb; 57(1):91-96. PubMed ID: 29398508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
